UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes

The New England journal of medicine, 2018-05, Vol.378 (20), p.1908-1919

2018

Volltextzugriff (PDF)

First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor

Clinical and translational science, 2024-05, Vol.17 (5), p.e13789-n/a

2024

Volltextzugriff (PDF)

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation

Transplant international, 2012-05, Vol.25 (5), p.592-602

2012

Volltextzugriff (PDF)

Adult onset Still’s disease—The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)

Seminars in arthritis and rheumatism, 2017-10, Vol.47 (2), p.295-302

2017

Volltextzugriff (PDF)

Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy

Clinical and experimental nephrology, 2014-02, Vol.18 (1), p.135-143

2014

Volltextzugriff (PDF)

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

The Lancet (British edition), 2022-01, Vol.399 (10320), p.161-171

2022

Volltextzugriff (PDF)

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride

Nephrology (Carlton, Vic.), 2011-11, Vol.16 (8), p.743-750

2011

Volltextzugriff (PDF)

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Kidney international, 2024-01, Vol.105 (1), p.189-199

2024

Volltextzugriff (PDF)

Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study

Transplantation, 2015-07, Vol.99 (7), p.1455-1462

2015

Volltextzugriff (PDF)

Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity

Pediatric rheumatology online journal, 2015-11, Vol.13 (47), p.50-50, Article 50

2015

Volltextzugriff (PDF)

Open‐Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome

Arthritis & rheumatology (Hoboken, N.J.), 2017-08, Vol.69 (8), p.1679-1688

2017

Volltextzugriff (PDF)

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial

The Lancet. Haematology, 2021-05, Vol.8 (5), p.e344-e354

2021

Volltextzugriff (PDF)

Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function

Clinical and experimental immunology, 2023-10, Vol.213 (3), p.265-275

2023

Volltextzugriff (PDF)

Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study

Rheumatology (Oxford, England), 2017-09, Vol.56 (9), p.1484-1491

2017

Volltextzugriff (PDF)

Comment on: Real-life effectiveness of canakinumab in cryoprin-associated periodic syndrome

Rheumatology (Oxford, England), 2016-07, Vol.55 (7), p.1340-1341

2016

Volltextzugriff (PDF)

Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation

Transplantation, 2017-02, Vol.101 (2), p.341-349

2017

Volltextzugriff (PDF)

Comment on: real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome: reply

Rheumatology (Oxford, England), 2016-07, Vol.55 (7), p.1340-1341

2016

Volltextzugriff (PDF)

Graft versus host disease after liver transplantation – a single center experience and review of literature

Transplant international, 2008-05, Vol.21 (5), p.441-451

2008

Volltextzugriff (PDF)

Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation

Clinical transplantation, 2006-05, Vol.20 (3), p.272-283

2006

Volltextzugriff (PDF)

Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator?

Transplantation proceedings, 2002-08, Vol.34 (5), p.1542-1543

2002

Volltextzugriff (PDF)

The Contribution of Protease-Activated Receptor 1 to Neuronal Damage Caused by Transient Focal Cerebral Ischemia

Proceedings of the National Academy of Sciences - PNAS, 2003-10, Vol.100 (22), p.13019-13024

2003

Volltextzugriff (PDF)

Activation of protease activated receptor 1 increases the excitability of the dentate granule neurons of hippocampus

Molecular brain, 2011-08, Vol.4 (1), p.32-32, Article 32

2011

Volltextzugriff (PDF)

Plasmin Potentiates Synaptic N-Methyl-D-aspartate Receptor Function in Hippocampal Neurons through Activation of Protease-activated Receptor-1

The Journal of biological chemistry, 2008-07, Vol.283 (29), p.20600-20611

2008

Volltextzugriff (PDF)

Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival

Haematologica (Roma), 2009-10, Vol.94 (10), p.1453-1455

2009

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Humans
(23)
Life Sciences & Biomedicine
(23)
Male
(16)
Female
(15)
Adult
(13)
Middle Aged
(12)
Treatment Outcome
(11)
Rheumatology
(8)
Aged
(7)
Surgery
(6)
Transplantation
(6)
Adolescent
(5)
Dose-Response Relationship, Drug
(5)
Double-Blind Method
(5)
Immunology
(5)
Time Factors
(5)
Young Adult
(5)
Antibodies, Monoclonal - Therapeutic Use
(4)
Drug Dosages
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes

First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation

Adult onset Still’s disease—The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)

Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study

Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity

Open‐Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial

Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function

Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study

Comment on: Real-life effectiveness of canakinumab in cryoprin-associated periodic syndrome

Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation

Comment on: real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome: reply

Graft versus host disease after liver transplantation – a single center experience and review of literature

Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation

Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator?

The Contribution of Protease-Activated Receptor 1 to Neuronal Damage Caused by Transient Focal Cerebral Ischemia

Activation of protease activated receptor 1 increases the excitability of the dentate granule neurons of hippocampus

Plasmin Potentiates Synaptic N-Methyl-D-aspartate Receptor Function in Hippocampal Neurons through Activation of Protease-activated Receptor-1

Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival

Aktive Filter

Suchergebnisse filtern